Acellular Dermal Matrix(SureDerm BCS) in Breast-Conserving Surgery for Breast Cancer Patients

Inclusion Criteria: * Female patients aged 20 to 75 years * Diagnosed with unilateral breast cancer (ICD-10 code: C50, D05) and treated with breast-conserving surgery * Agreed to the use of acellular dermal matrix (ADM) during surgery * Histologically confirmed primary breast cancer * Patients who received neoadjuvant chemotherapy are eligible * Planned to receive standard postoperative treatment, including adjuvant radiotherapy * Voluntarily decided to participate in the study and provided written informed consent Exclusion Criteria: * Evidence of distant metastasis * Presence of infectious disease, autoimmune disease (e.g., specific rheumatologic disorders), or bleeding/coagulation disorders * Known adverse reactions to all first-line antibiotics * Suspected inflammatory infection of the breast prior to surgery * Pregnant women at the time of enrollment * Definite contraindications to the use of acellular dermal matrix * Contraindications to radiotherapy * Male patients * History of another malignancy diagnosed within the past 5 years * Patients deemed unsuitable for participation due to difficulty in data collection as judged by the investigator * Patients unable to understand or complete the study questionnaires